TRUSYNERGY

Lobbying for BURRELL INTERNATIONAL GROUP (ON BEHALF OF AMO PHARMA) · Life Sciences R&D

Filing 4th Quarter - Report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 9, 2026

Money reported

None

Registrations and no-activity reports carry no figure.

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Lobbying activity 1

Health Issues

Clinical trial guidance for ultra-rare and rare diseases.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.